Literature DB >> 26795287

Noninvasive Imaging of Islet Transplants with 111In-Exendin-3 SPECT/CT.

Inge van der Kroon1, Karolina Andralojc2, Stefanie M A Willekens2, Desirée Bos2, Lieke Joosten2, Otto C Boerman2, Maarten Brom2, Martin Gotthardt2.   

Abstract

UNLABELLED: Islet transplantation is a promising treatment for type 1 diabetic patients. However, there is acute as well as chronic loss of islets after transplantation. A noninvasive imaging method that could monitor islet mass might help to improve transplantation outcomes. In this study, islets were visualized after transplantation in a rat model with a dedicated small-animal SPECT scanner by targeting the glucagonlike peptide-1 receptor (GLP-1R), specifically expressed on β-cells, with (111)In-labeled exendin-3.
METHODS: Targeting of (111)In-exendin-3 to GLP-1R was tested in vitro on isolated islets of WAG/Rij rats. For in vivo evaluation, 400 or 800 islets were transplanted into the calf muscle of WAG/Rij rats (6-8 wk old). Four weeks after transplantation, SPECT/CT images were acquired 1 h after injection of (111)In-labeled exendin-3. After SPECT acquisition, the muscles containing the transplant were analyzed immunohistochemically and autoradiographically.
RESULTS: The binding assay, performed on isolated islets, showed a linear correlation between the number of islets and (111)In-exendin-3 accumulation (Pearson r = 0.98). In vivo, a 1.70 ± 0.44-fold difference in tracer uptake between 400 and 800 transplanted islets was observed. Ex vivo analysis of the islet transplant showed colocalization of tracer accumulation on autoradiography, with insulin-positive cells and GLP-1R expression on immunohistochemistry.
CONCLUSION: (111)In-exendin-3 accumulates specifically in the β-cells after islet transplantation and is a promising tracer for noninvasive monitoring of the islet mass.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  GLP-1R; SPECT; exendin-3; islet imaging; islet transplantation

Mesh:

Substances:

Year:  2016        PMID: 26795287     DOI: 10.2967/jnumed.115.166330

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Non-invasive in vivo determination of viable islet graft volume by 111In-exendin-3.

Authors:  Wael A Eter; Inge Van der Kroon; Karolina Andralojc; Mijke Buitinga; Stefanie M A Willekens; Cathelijne Frielink; Desiree Bos; Lieke Joosten; Otto C Boerman; Maarten Brom; Martin Gotthardt
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

2.  Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.

Authors:  Takaaki Murakami; Hiroyuki Fujimoto; Naotaka Fujita; Keita Hamamatsu; Daisuke Yabe; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2020-06-01       Impact factor: 4.232

Review 3.  In Vivo Imaging of Pancreatic Islet Grafts in Diabetes Treatment.

Authors:  Dian R Arifin; Jeff W M Bulte
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-02       Impact factor: 5.555

4.  Recent progress in the use and tracking of transplanted islets as a personalized treatment for type 1 diabetes.

Authors:  Genaro A Paredes-Juarez; Paul de Vos; Jeff W M Bulte
Journal:  Expert Rev Precis Med Drug Dev       Date:  2017-03-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.